Biotest Aktiengesellschaft

WBAG:BIO3 Stock Report

Market Cap: €1.4b

Biotest Past Earnings Performance

Past criteria checks 1/6

Biotest has been growing earnings at an average annual rate of 51.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 11.5% per year. Biotest's return on equity is 13%, and it has net margins of 9.7%.

Key information

51.8%

Earnings growth rate

53.8%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate11.5%
Return on equity13.0%
Net Margin9.7%
Next Earnings Update28 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biotest makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WBAG:BIO3 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24707698568
30 Jun 247811648765
31 Mar 247831778671
31 Dec 236851278467
30 Sep 23656918456
30 Jun 23538-108557
31 Mar 23517-478450
31 Dec 22516-328251
30 Sep 22505-698451
30 Jun 22511-658350
31 Mar 22512-548251
31 Dec 21516-638252
30 Sep 21514-287755
30 Jun 21507-337855
31 Mar 21507-358056
31 Dec 20484-318056
30 Sep 20466-348256
30 Jun 20459-248454
31 Mar 20439-158352
31 Dec 19419-58353
30 Sep 19406-98252
30 Jun 19395-38253
31 Mar 19390-68251
31 Dec 18400-138549
30 Sep 18405189150
30 Jun 1840969152
31 Mar 1840019954
31 Dec 17378-1610055
30 Sep 17257-489556
30 Jun 17301-479352
31 Mar 17340-298949
31 Dec 1640868848
30 Sep 165311287836
30 Jun 16525528862
31 Mar 16526368872
31 Dec 15535279379
30 Sep 15590-8810793
30 Jun 15606310973
31 Mar 156021611069
31 Dec 145821910867
30 Sep 145432710572
30 Jun 14522319869
31 Mar 14504309567
31 Dec 13501329365

Quality Earnings: BIO3 has a large one-off gain of €14.8M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: BIO3's current net profit margins (9.7%) are lower than last year (13.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIO3 has become profitable over the past 5 years, growing earnings by 51.8% per year.

Accelerating Growth: BIO3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIO3 had negative earnings growth (-24.6%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).


Return on Equity

High ROE: BIO3's Return on Equity (13%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies